Business Insider

Cellceutix’s Phase 2 Drug Candidate Brilacidin Emerging as a Potential Novel Non-Biologic Therapy in Treating Inflammatory Bowel DiseaseStudy to help guide Cellceutix in ...

BEVERLY, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, ...
Seeking Alpha

Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases

WAKEFIELD, MA, June 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced the United States ...